Negative
24Serious
Neutral
Optimistic
Positive
- Total News Sources
- 2
- Left
- 1
- Center
- 0
- Right
- 1
- Unrated
- 0
- Last Updated
- 45 days ago
- Bias Distribution
- 50% Right


FDA Warns Against Unapproved Compounded GLP-1 Weight Loss Drugs Amid Safety Reports
Recent studies highlight the effectiveness and additional benefits of GLP-1 receptor agonist drugs for weight loss and related behaviors. A study published in the New England Journal of Medicine found that tirzepatide (marketed as Zepbound) led to significantly greater weight loss—about 20% of body weight over 72 weeks—compared to semaglutide (Ozempic/Wegovy), which resulted in about 14% weight loss. Another study reported that combining semaglutide with personalized, app-based support allowed patients to achieve similar weight loss at roughly half the usual drug dose, potentially reducing side effects and costs. Meanwhile, research from the European Congress on Obesity demonstrated that patients using GLP-1 drugs such as semaglutide or liraglutide reduced their alcohol intake by nearly two-thirds within four months, likely due to these drugs' effects on brain regions controlling cravings. However, the FDA has issued warnings against unapproved compounded versions of GLP-1 drugs due to safety risks, dosing errors, and serious adverse events. These findings underscore both the promise and the need for caution in the expanding use of GLP-1 medications for obesity and related conditions.


- Total News Sources
- 2
- Left
- 1
- Center
- 0
- Right
- 1
- Unrated
- 0
- Last Updated
- 45 days ago
- Bias Distribution
- 50% Right
Negative
24Serious
Neutral
Optimistic
Positive
Related Topics
Stay in the know
Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Gift Subscriptions
The perfect gift for understanding
news from all angles.